Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice

Journal of the Canadian Urological Association

Volumn 6, Issue 6, 2012, Pages 465-470

  So, Alan ^a   Chin, Joseph ^b   Fleshner, Neil ^c   Saad, Fred ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84875074661     PISSN: 19116470     EISSN: None     Source Type: Journal    
DOI: 10.5489/cuaj.117     Document Type: Article

References (42)

1. Prostate Cancer Statistics at a glance. Canadian Cancer Society; 2011. http://www.cancer.ca. Accessed November 21, 2012.
2. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20. http://dx.doi.org/10.1056/NEJMoa041318
3. Scher HI, Morris MJ, Kelly WK, et al. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 2005;11:5223-32.
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12. http://dx.doi.org/10.1056/NEJMoa040720
5. Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 2003;9:2394-9.
6. Lipton A. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. J Support Oncol 2004;2:205-13; discussion 213-4, 216-7, 219-20.
7. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(8 Suppl):1588-94. http://dx.doi.org/10.1002/(SICI)1097-0142(19971015)80:8+1588::AID-CNCR93.0.CO;2-G
8. Saad F, Gleason DM, Murray R, et al. Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer. J Natl Cancer Inst 2004;96:879-82. http://dx.doi.org/10.1093/jnci/djh141
9. Tchekmedyian NS, Chen YM, Saad F. Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors. Cancer Invest 2010;28:849-55. http://dx.doi.org/10.3109/07357907.2010.483508
10. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69. http://dx.doi.org/10.1093/jnci/dji002
11. Fohr B, Dunstan CR, Seibel MJ. Clinical review 165: Markers of bone remodeling in metastatic bone disease. J Clin Endocrinol Metab 2003;88:5059-75. http://dx.doi.org/10.1210/jc.2003-030910
12. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005;16:579-84.
13. Krupski TL, Foley KA, Baser O, et al. Health care cost associated with prostate cancer, androgen depriva-tion therapy and bone complications. J Urol 2007;178(4 Pt 1):1423-8. http://dx.doi.org/10.1016/j.juro.2007.05.135
14. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94:1458-68. http://dx.doi.org/10.1093/jnci/94.19.1458
15. Bogardus ST Jr, Towle V, Williams CS, et al. What does the medical record reveal about functional status? A comparison of medical record and interview data. J Gen Intern Med 2001;16:728-36. http://dx.doi.org/10.1111/j.1525-1497.2001.00625.x
16. Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007;110:1860-7. http://dx.doi.org/10.1002/cncr.22991
17. Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005-7. http://dx.doi.org/10.1016/S0022-5347(05)64561-2
18. Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 2003;51:364-70. http://dx.doi.org/10.1046/j.1532-5415.2003.51110.x
19. O'Neill TW, Roy DK. How many people develop fractures with what outcome? Best practice & research. Clin Rheum 2005;19:879-95. http://dx.doi.org/10.1016/j.berh.2005.06.003
20. Fizazi K, Bosserman L, Gao G, et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009;182:509-15; discussion 515-6.
21. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer 1999;7:271-9.
22. Health Canada. Notice of Compliance for denosumab (XGeva) for advanced prostate cancer 2011.
23. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132-9.
24. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-22. http://dx.doi.org/10.1016/S0140-6736(10)62344-6
25. Health Canada. Notices of Compliance, January 1-December 31, 2002. 2002. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/txt/prodpharma/pre2002et.txt. Accessed November 26, 2012.
26. Saad F, Eastham J. Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 2010;76:1175-81. http://dx.doi.org/10.1016/j.urol-ogy.2010.05.026
27. Suominen MI, Rissanen JP, Käkönen R, et al. Alpharadin inhibits osteoclast differentiation in vitro and progression of established breast cancer bone metastases in vivo. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, Florida. Philadelphia (PA): AACR; 2011. Abstract 2664.
28. Parker C, Heinrich D, O'Sullivan JM, et al. Overall Survivial Benefit of Radium-223 Chloride (AlpharadinTM) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-Resistant Prostate CAncer (CRPC): A Phase III Randomised Trial (ALSYMPCA). In: Proceedings of the European Society of Medical Oncology; 2011 May 16-19; Providence (RI).
29. Health Canada. CDEC Final Recommendation, Denosumab (Xgeva-Amgen Canada Inc). Common Drug Review. 2011:1-5.
30. Network NCC. NCCN Clinical Practice Guidelines in Oncology 2011. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed November 26, 2012.
31. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on Prostate Cancer. 2011. http://www.uroweb.org/gls/pdf/08_Prostate_Cancer%20September%2022nd%202011.pdf. Accessed November 26, 2012.
32. Saad F, Hotte S. Guidelines for the management of castrate-resistant prostate cancer. CUA Guideline. Can Urol Assoc J 2010;4:380-4.
33. Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012;379:39-46. Epub 2011 Nov 15.
34. Polascik TJ. Bone health in prostate cancer patients receiving androgen-deprivation therapy: the role of bisphosphonates. Prostate Cancer Prostatic Dis 2008;11:13-9. http://dx.doi.org/10.1038/sj.pcan.4501019
35. Health Canada. Health Canada Endorsed Important Safety Information on XGEVA(R) (denosumab). http://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2012/xgeva_hpc-cps-eng.php. (Accessed November 26, 2012).
36. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012;23:1341-7. Epub 2011 Oct 10.
37. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-32.
38. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76.
39. Saad F, Chen YM, Gleason DM, et al. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 2007;5:390-6. http://dx.doi.org/10.3816/CGC.2007.n.022
40. Stopeck AT, Lipton A, Martin M, et al. Denosumab in Patients With Breast Cancer and Bone Metastases Previously Treated With Zoledronic Acid or Denosumab: Results From the 2-Year Open-Label Extension Treatment Phase of a Pivotal Phase 3 Study. In: Proceedings from the San Antonio Breast Cancer Symposium 2011.
41. Dearnaley DP, Sydes MR, Mason MD, et al. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst 2003;95:1300-11. http://dx.doi.org/10.1093/jnci/djg038
42. Small EJ, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 2003;21:4277-84.